Stroke – Pipeline Review, H2 2018 – ResearchByMarkets.com

September 14, 2018 /ResearchByMarkets/— “Stroke – Pipeline Review, H2 2018“, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. 

Report Highlights

Stroke – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 26, 23, 2, 104, 15 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 4 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/34126

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
– The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Companies Mentioned: 
Acorda Therapeutics Inc
Acticor Biotech SAS
Addex Therapeutics Ltd
Affibody AB
Amarantus Bioscience Holdings Inc
Anavex Life Sciences Corp
Antoxis Ltd
Apellis Pharmaceuticals Inc
AptaTargets SL
ArmaGen Inc
Artelo Biosciences Inc
ArunA Biomedical Inc
AstraZeneca Plc
Athersys Inc
BioAxone BioSciences Inc
Biogen Inc
BioTime Inc
Boehringer Ingelheim GmbH
Cardax Inc
Celltrion Inc
CHA Bio & Diostech Co Ltd
CohBar Inc
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Diffusion Pharmaceuticals Inc
Epigen Biosciences Inc
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Fina Biotech SL
Freeox Biotech SL
GC Pharma
Genervon Biopharmaceuticals LLC
Glialogix Inc
Glucox Biotech AB
Immunwork Inc
Instituto Biomar SA
International Stem Cell Corp
Jeil Pharmaceutical Co Ltd
JT Pharmaceuticals Inc
Les Laboratoires Servier SAS
Living Cell Technologies Ltd
Lixte Biotechnology Holdings Inc
Lumosa Therapeutics Co Ltd
M et P Pharma AG
Mapreg SAS
Meridigen Biotech Co Ltd
Neuralstem Inc
Neuren Pharmaceuticals Ltd
Neurofx Inc
NeuroNascent Inc
NeurOp Inc
New World Laboratories Inc
Nipro Corp
NoNO Inc
Novartis AG
NuvOx Pharma LLC
Nyrada Inc
Pharmagenesis Inc
Pharmicell Co Ltd
Phoenix Biotechnology Inc
PhytoHealth Corp
Prolong Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
RegeneRx Biopharmaceuticals Inc
ReNetX Bio
ReNeuron Group Plc
Reven Pharmaceuticals Inc
Rich Pharmaceuticals Inc
Rubicon Biotechnology Inc
Saneron CCEL Therapeutics Inc
Saniona AB
Savara Inc
Shin Poong PharmCo Ltd
Shionogi & Co Ltd
Simcere Pharmaceutical Group
Stemedica Cell Technologies Inc
SynZyme Technologies LLC
TaiGen Biotechnology Co Ltd
Tasly Pharmaceutical Group Co Ltd
Tenax Therapeutics Inc
The Cell-Factory BVBA
Thrombolytic Science International LLC
TikoMed AB
Toyama Chemical Co Ltd
Vect-Horus SAS
Verseon Corp
Vicore Pharma AB
Virogenomics BioDevelopment Inc
WhanIn Pharmaceutical Co Ltd
Zensun (Shanghai) Sci & Tech Co Ltd
Zocere Inc
ZZ Biotech LLC

Get in touch with us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.